LYEL earnings: real EPS beat/miss history, analyst consensus Buy, P/E -0.76. Updated 2026-07-23.
Lyell Immunopharma (LYEL) Research Hub
Lyell Immunopharma (LYEL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.96 USD (-7.14%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.76, market cap 0.31B. This hub links to the full technical, earnings and options research available for LYEL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.96 USD (-7.14%) |
| 52-week range | 11.47 USD – 17.15 USD |
| Trend regime | Range |
| 14-day RSI | 31.9 (Bearish) |
| Trailing P/E | -0.76 |
| Market cap | 0.31B |
| Dividend yield | 0.00% |
Available research for LYEL
Covered Call on LYEL: how it works, illustrative setup around the real 11.96 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LYEL: how it works, illustrative setup around the real 11.96 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LYEL: how it works, illustrative setup around the real 11.96 USD price, max profit/loss, breakeven and when to use it. Educational.
LYEL technical analysis: range, last 11.96 USD, RSI 31.9, 52w range 11.47 USD–17.15 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is LYEL in?
Lyell Immunopharma (LYEL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LYEL in an uptrend or downtrend?
As of 2026-09-11, LYEL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LYEL's trailing P/E ratio?
LYEL's trailing P/E is -0.76, with a market cap of 0.31B. See the earnings research page for full valuation detail.